The misuse of and addiction to opioids constitute an unprecedent crisis in the US with devasting consequences affecting public health as well as social and economic welfare. In this context, there is an urgent need to help patients using opioid medications to quit opioids. A new treatment facilitating detoxification will have a tremendous effect and help overcome the current opioid crisis. 

We are developing first-in-class small molecule antagonists of NPFF receptor to address multiple aspects of the current opioid crisis.

Program description

NPFFR antagonist

  • Discovery
  • Candidate
  • Preclinical
  • Clinical

NPFF pathway is part of the anti-opioid system balancing endogenously opioid activation. Dysregulation of this balance is involved in the development of hyperalgesia, opioid tolerance, central pain sensitization, and addiction to opioids.

Domain’s NPFFR antagonist program, originating from the university of Strasbourg in France, is currently in lead optimization phase. Animal proof-of-concept studies as well as evaluations through the Addiction Treatment Discovery Program at the National Institute for Drug Abuse (ATDP-NIDA) have shown that NPFFR antagonist holds strong potential to become a disease-modifying treatment in chronic pain and in opioid detoxification.

Other Programs

mGluR4/7/8 positive allosteric modulator for Parkinson’s disease


PAR2 negative allosteric modulator for rare inflammatory diseases